Pep IQ
← Pep IQ
Sports medicine clinicians, regenerative medicine practitioners, named protocols and a decade-plus of community use converge tightly on 250–500 mcg/day SubQ for 4–8 weeks. Andrew Huberman recommends 300–500 mcg, 2–3× per week, for 8 weeks. Some protocols use a brief loading approach of 300 mcg/day for the first 4 weeks dropping to 200 mcg/day for maintenance — but loading stays within the same dose range, not orders of magnitude higher. Oral dosing (250–500 mcg/day) is preferred for gut issues; SubQ near the injury site for soft tissue. BPC-157 + TB-500 stacking (250 mcg BPC + 2–2.5 mg TB-500 twice weekly) is common in regenerative settings for serious soft-tissue injury. This is the largest population stream — thousands of users running this dose range over years, with a low adverse-event signal and consistent recovery reports across independent communities (sports medicine, post-surgical recovery, gut health, gym-going population).
Three published human studies. A pilot study used IV infusions up to 20 mg in healthy adults with no adverse events recorded — a controlled trial setting, not a recommended self-use protocol. A small clinical study (n=12) showed 7 of 12 patients with chronic knee pain achieved 6+ months of relief from a single intra-articular injection. The human RCT base is the smallest of the evidence streams. It doesn't contradict the animal or community pattern, but it doesn't carry the weight on its own — the community use stream is doing the heavy lifting for what we know about real-world tolerability.
A 2025 systematic review catalogued 36 studies — 35 preclinical and 1 clinical — showing consistent benefits across musculoskeletal injury models: tendon healing, ligament repair, muscle injury recovery, fracture healing, and reduced inflammation. The original Sikiric body of work (over 100 controlled studies in rats, rabbits, and mice) used 10 ng/kg–10 mcg/kg daily or every-other-day injection, with healing typically observed within 7–14 days. This is one of the largest preclinical evidence bases for any healing peptide. Caveat: the research base is dominated by a single group; independent replication of the key findings is limited.
BPC-157 has a credible mechanism, the largest preclinical evidence base of any healing peptide, and consistent clinical and community protocols converging on 250–500 mcg/day SubQ for 4–8 weeks across thousands of users. Higher doses (1 mg/day or above) appear in some athlete circles for severe injury but are not represented in published literature, systematic reviews, or named clinical practice — Pep IQ does not endorse those protocols. Stop when the injury heals; no long-term human safety data exists for chronic continuous use.
BPC-157 is a synthetic 15 amino acid peptide derived from a protein called BPC — Body Protection Compound — first isolated from human gastric juice in the early 1990s by Croatian researcher Predrag Sikiric and his team at the University of Zagreb. The gastric origin is significant: gastric juice contains peptides specifically evolved to protect and repair the gut lining, and BPC-157 appears to be the active fragment responsible for much of that cytoprotective activity.
What makes BPC-157 scientifically unusual is its stability. Most peptides are rapidly destroyed by stomach acid — BPC-157 is not. It is resistant to hydrolysis in gastric juice, which is why it can be taken orally (unlike most peptides) as well as by injection. It has no sequence homology with any other known gut peptide, which makes it structurally distinctive.
The research base is simultaneously extensive and narrow. Over 30 years of published studies exist — almost entirely in rodents, almost entirely from Sikiric's group in Croatia. This single-group provenance is one of the most frequently raised concerns in critical reviews: when virtually all the data comes from one research team, independent replication is not possible, and conflicts of interest are harder to rule out.
The single-source problem: A 2026 investigative report by STAT News found that nearly all BPC-157 animal research originates from one Croatian research group. A 2015 Phase I human trial registered by the same group submitted data to clinicaltrials.gov but then withdrew it before peer review — and the results have never been published. The lead researcher declined repeated interview requests. This is important context for evaluating the literature.
BPC-157 has been studied across an unusually wide range of biological systems — gut, tendon, bone, heart, brain, liver, kidney, cornea. Critics note that a compound claimed to benefit almost everything should trigger scepticism. Supporters counter that its broad effects reflect a fundamental cytoprotective mechanism acting upstream of many specific pathologies.
Clinical trials. Published human work on BPC-157 has been small in scale and narrow in scope. The most-cited dosing reference is around 10 mcg/kg via intramuscular injection, drawn from extrapolations of the Sikiric group's Croatian rat work and a handful of small human pilots in IBD and joint injury. Trial doses have ranged from microgram-per-kilo IM injections up to 20mg single-dose IV in safety studies. Total published human subjects across all known trials remain under 30 — no large RCT exists.
Community-reported. Real-world dosing among self-experimenting users converges on 250–1000 mcg/day, most commonly delivered subcutaneously, with 500 mcg/day appearing as the typical reported dose across long-running peptide forums and self-tracked logs. Oral arginate-stable BPC-157 (Arg-BPC-157) is reported at higher doses — 500 mcg to 1 mg daily — for gut-targeted use, since less of the oral dose reaches systemic circulation. Bloods on standard panels (CBC, CMP, lipids, hsCRP) generally show no consistent shifts at these doses, which most users interpret as a safety signal rather than absence of effect.
Why the gap. The trial dose was set in animal models scaled to human body weight, not titrated through human dose-response work. The community dose evolved through years of self-experimentation, with users typically starting low (250 mcg) and scaling based on perceived effect. Neither figure is "correct" — they answer different questions. Trials show what was tested in narrow controlled conditions; community reports show what works for thousands of people across varying ages, body weights, conditions, and stacks. Pep IQ shows both because the gap itself is information.
The clinical and community-reported pattern hasn't stayed static. A decade of population use has refined the original dose ranges in a handful of consistent directions, and these patterns are now visible across independent sources — sports medicine practitioners, regenerative clinics, long-running peptide communities, and self-tracked logs converging on the same conclusions without coordinating.
Doses came down, not up. Early podcast-era community protocols pushed 1 mg/day or higher as a default. The current converged range across most reference sources sits at 250–500 mcg/day for soft tissue, with higher only used short-term for severe acute injury. The simplest reading: at the convergence dose, recovery results are reproducible without dose-related side-effect reports increasing — there's no community-driven incentive to push higher for the average use case.
Local-near-injury SubQ became the default for soft tissue. Early protocols were less specific about injection site. The current consensus across sports medicine practice is SubQ within a few inches of the injury for tendon, ligament and muscle work. Oral (Arg-BPC-157) is the default for gut-targeted use, since less systemic exposure matters when the tissue is gut lining.
Cycle length, not continuous use. The community has consistently moved toward defined 4–8 week cycles with a clear stop signal (injury healed, symptom resolved) rather than rolling continuous use. Where longer use comes up, it's typically for chronic gut conditions rather than musculoskeletal work, and tends to stay at the lower end of the dose range.
BPC-157 + TB-500 stacking emerged from regenerative medicine practice for serious soft-tissue and joint injury — 250 mcg BPC near the injury site, 2–2.5 mg TB-500 systemic, twice weekly. This is one of the most-discussed stacks in the recovery community and is now standard in named "Wolverine" protocols across multiple reference sources.
Bias note. Community evidence has known biases — people who stopped early are under-represented, some original dose conventions started from supplier recommendations, and self-reports skew toward perceived success. Naming this is not a reason to discount the pattern; the convergence across independent groups (clinical, regenerative, self-experimenters) is what gives the signal weight. Where the population stream and the formal trial base disagree, we say so. On BPC-157 they don't — they're consistent with each other within the limits of what each stream can resolve.
BPC-157 is one of two free reference entries. The other 69 — plus 20 protocol references, a dose tracker, and weekly updates — are included with membership. Less than 35p a day.
Start 30-day Free Trial →